|June 2009 (Volume 16, Issue 6)
U.S. Sites Rate Medpace, Kendle, ICON as Top CROs in 2009
Medpace, a private CRO on the rise, has been rated number one by U.S. investigative sites that it works with. Kendle, which came in second, has ranked in the top three in CenterWatch’s survey the past three years, but was recently hit by a large number of project cancellations. Third place ICON returns to the top three for the first time since 2005.
Pediatric Trials Move Toward Global Collaboration
As drug sponsors struggle to comply with new U.S and European regulations for pediatric studies, the FDA and EMEA have been working to coordinate global pediatric trials. Finding enough pediatric patients for these studies is a challenge and often requires multinational studies.
European Biotech Sector Struggles to Survive Funding Crisis
One in five European small biopharmaceutical companies faces the risk of bankruptcy by the end of 2009. The situation could worsen if the economic downturn continues into 2010, warns the European Biopharmaceutical Enterprise (EBE), the trade group representing 63 companies in the European biotechnology sector. What is befalling the biotech sector could have a ripple effect on the bottom lines of contract research organizations (CROs), especially those that cater mainly to the biotech sector.
Eye On: Gastrointestinal Diseases
Gastrointestinal diseases may affect different sites in the entire digestive system from the mouth to the esophagus, stomach, small intestine, colon, rectum and anus.